The DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Tau Kinetics in Neurons and the Human Central Nervous System
Open accessAbstract
We developed stable isotope labeling and mass spectrometry approaches to measure the kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) and in human induced pluripotent stem cell (iPSC)-derived neurons. Newly synthesized tau is truncated and released from human neurons in 3 days. Although most tau proteins have similar turnover, 4R tau isoforms and phosphorylated forms of tau exhibit faster turnover rates, suggesting unique processing of these forms that may have independent biological activities. The half-life of tau in control human iPSC-derived neurons is 6.74 ± 0.45 days and in human CNS is 23 ± 6.4 days. In cognitively normal and Alzheimer's disease participants, the production rate of tau positively correlates with the amount of amyloid plaques, indicating a biological link between amyloid plaques and tau physiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“One of the significant hurdles in modeling AD with iPSC-derived neurons or NGN2-induced neurons for the past decade has been their inability to produce the 4R Tau isoform found in adult human brains [19–22]; only the fetal 0N3R splicing isoform is produced, even after one year of differentiation [19].”
From Elevated SGK1 increases Tau phosphorylation and microtubule instability in Alzheimer’s patient-derived cortical neurons (2026) · cites this paper as [22]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, fetal neurons and iPSCs-derived neurons primarily express 3R-tau (20, 21)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF tau species precede tau positron emission tomography (PET) abnormalities by a decade.18,19”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, in relation to sporadic AD, this study adds further support to the hypothesis that CSF p-tau is closely related to Aβ-mediated tau release from neurons19 and challenges the notion of being simply a state marker of NFT.”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sato et al36 report that in the human central nervous system, P-tau exhibits a faster turnover rate, which likely explains the elevated CSF level of this protein in various neurodegenerative conditions.”
From Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia (2020) · cites this paper as [36]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“This is important because little 4R tau is expressed in induced pluripotent stem cell (iPSC)-derived models without a splice-site mutation (lovino et al., 2015; Sato et al., 2018; Sposito et al., 2015; Verheyen et al., 2018).”
From ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids (2021) · cites this paper as Sato et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“Instead, evidence now documents active secretion of tau in normal and disease conditions.19,65”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationStaging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,133
Cryo-EM structures of tau filaments from Alzheimer’s disease
Fitzpatrick, A. W. P., Falcon, B., He, S., Murzin, A. G., Murshudov, G., Garringer, H. J., Crowther, R. A., Ghetti, B., Goedert, M., & Scheres, S. H. W. (2017) · Nature · doi:10.1038/nature23002 · Cited by 2,061
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252
Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110
Flagged first, then by citations
1 of the 82 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 584
Hu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Self-citationCorsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
Initiative, T. A. D. N., Guo, Y., Huang, Y., Shen, X., Chen, S.-D., Hu, H., Wang, Z.-T., Tan, L., & Yu, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00834-3 · Cited by 45
VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease
Weidung, B., Hemmingsson, E., Olsson, J., Sundström, T., Blennow, K., Zetterberg, H., Ingelsson, M., Elgh, F., & Lövheim, H. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12264 · Cited by 40
Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 41
Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain
Detrez, J. R., Maurin, H., Van Kolen, K., Willems, R., Colombelli, J., Lechat, B., Roucourt, B., Van Leuven, F., Baatout, S., Larsen, P., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.010 · Cited by 39
Hirota, Y., Sakakibara, Y., Ibaraki, K., Takei, K., Iijima, K., & Sekiya, M. (2022) · Brain Communications · doi:10.1093/braincomms/fcac286 · Cited by 41
To target Tau pathologies, we must embrace and reconstruct their complexities
Limorenko, G., & Lashuel, H. A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105536 · Cited by 41
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Zhang, L., Xia, Y., & Gui, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1199434 · Cited by 41
Lopes, J. R. D., Zhang, X., Mayrink, J., Tatematsu, B. K., Guo, L., LeServe, D. S., Abou‐El‐Hassan, H., Rong, F., Dalton, M. J., Oliveira, M. G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309221120 · Cited by 38
Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00741-9 · Cited by 42
Lewis, J. M., Alattar, A. A., Akers, J. C., Carter, B. S., Heller, M. J., & Chen, C. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-46311-8 · Cited by 38
Llibre‐Guerra, J. J., Li, Y., Schindler, S. E., Gordon, B. A., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., Hassenstab, J. J., Wang, G., Allegri, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17126 · Cited by 40
Self-citationAnother step forward in blood-based diagnostics for Alzheimer’s disease
Bateman, R. J., Barthélemy, N. R., & Horie, K. (2020) · Nature Medicine · doi:10.1038/s41591-020-0797-4 · Cited by 37
Self-citationCongdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 38
Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis
Gaur, A., Rivet, L., Mah, E., Bawa, K. K., Gallagher, D., Herrmann, N., & Lanctôt, K. L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102046 · Cited by 37
Tau truncation in the pathogenesis of Alzheimer’s disease: a narrative review
Chu, D., Yang, X., Wang, J., Zhou, Y., Gu, J., Miao, J., Wu, F., & Liu, F. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385853 · Cited by 39
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 38
CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
Düzel, E., Berron, D., Schütze, H., Cárdenas‐Blanco, A., Metzger, C. D., Betts, M. J., Ziegler, G., Chen, Y., Dobisch, L., Bittner, D., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.10.003 · Cited by 37
Detection of all adult Tau isoforms in a 3D culture model of iPSC-derived neurons
Miguel, L., Rovelet‐Lecrux, A., Feyeux, M., Frébourg, T., Nassoy, P., Campion, D., & Lecourtois, M. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101541 · Cited by 37
Amro, Z., Yool, A. J., & Collins‐Praino, L. E. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100242 · Cited by 39
CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia
Heywood, W., Hällqvist, J., Heslegrave, A., Zetterberg, H., Fenoglio, C., Scarpini, E. A., Rohrer, J. D., Galimberti, D., & Mills, K. A. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.019 · Cited by 37
Galpern, W. R., Triana‐Baltzer, G., Li, L., Kolen, K. V., Timmers, M., Haeverans, K., Janssens, L., Kolb, H. C., Nandy, P., Aida, K., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.163 · Cited by 38
Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP
Nadel, C. M., Pokhrel, S., Wucherer, K., Oehler, A., Thwin, A. C., Basu, K., Callahan, M. D., Southworth, D. R., Mordes, D. A., Craik, C. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52075-1 · Cited by 36
Carroll, T., Guha, S. K., Nehrke, K. W., & Johnson, G. V. W. (2021) · Biology · doi:10.3390/biology10101047 · Cited by 39
Determining and interpreting protein lifetimes in mammalian tissues
Fornasiero, E. F., & Savas, J. N. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.08.011 · Cited by 35
Foiani, M. S., Cicognola, C., Ermann, N., Woollacott, I., Heller, C., Heslegrave, A., Keshavan, A., Paterson, R. W., Ye, K., Kornhuber, J., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319266 · Cited by 35
Relationship of Sleep Disorder with Neurodegenerative and Psychiatric Diseases: An Updated Review
Xiao, X., Rui, Y., Jin, Y., & Chen, M. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04086-5 · Cited by 35
Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons
Sanchez, C. G., Acker, C. M., Gray, A. J., Varadarajan, M., Song, C., Cochran, N. R., Paula, S., Lindeman, A., An, S., McAllister, G., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02272-1 · Cited by 37
McGrath, E. R., Beiser, A., O’Donnell, A., Yang, Q., Ghosh, S., Gonzales, M. M., Himali, J. J., Satizábal, C. L., Johnson, K. A., Tracy, R. P., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215639 · Cited by 37
Snellman, A., Ekblad, L. L., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Pietilä, E. A., Koivumäki, M., Helin, S., Karrasch, M., Zetterberg, H., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106175 · Cited by 36
Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
ADNI, Duits, F. H., Wesenhagen, K. E. J., Ekblad, L. L., Wolters, E. E., Willemse, E. A. J., Scheltens, P., van der Flier, W. M., Teunissen, C. E., Visser, P. J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00713-3 · Cited by 34
Barthélemy, N. R., Toth, B., Manser, P. T., Sanabria-Bohórquez, S., Teng, E., Keeley, M., Bateman, R. J., Weimer, R. M., & Wildsmith, K. R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210677 · Cited by 34
Self-citationSimrén, J., Brum, W. S., Ashton, N. J., Benedet, A. L., Karikari, T. K., Kvartsberg, H., Sjons, E., Lussier, F. Z., Chamoun, M., Stevenson, J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01142-0 · Cited by 34
Olczak, M., Poniatowski, Ł. A., Niderla‐Bielińska, J., Kwiatkowska, M., Chutorański, D., Tarka, S., & Wierzba‐Bobrowicz, T. (2019) · Forensic Science International · doi:10.1016/j.forsciint.2019.05.010 · Cited by 32
Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
Mengel, D., Janelidze, S., Glynn, R. J., Liu, W., Hansson, O., & Walsh, D. M. (2020) · Annals of Neurology · doi:10.1002/ana.25885 · Cited by 32
The Gut Microbiota-Brain Axis: A New Frontier on Neuropsychiatric Disorders
Queiroz, S. A. L., Ton, A. M. M., Pereira, T. D. M. C., Campagnaro, B. P., Martinelli, L., Picos, A., Campos‐Toimil, M., & Vasquez, E. C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.872594 · Cited by 34
Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 33
Role of sleep in neurodegeneration: the consensus report of the 5th Think Tank World Sleep Forum
Ferini‐Strambi, L., Liguori, C., Lucey, B. P., Mander, B. A., Spira, A. P., Videnović, A., Baumann, C. R., Franco, O. H., Fernandes, M., Gnarra, O., et al. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07232-7 · Cited by 34
Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2
Evans, L. D., Strano, A., Tuck, E., Campbell, A., Smith, J., Hung, C., Behr, T. S., Ghetti, B., Ryskeldi-Falcon, B., Karakoc, E., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00514-0 · Cited by 16
Alzheimer’s in a dish – induced pluripotent stem cell-based disease modeling
de Leeuw, S., & Tackenberg, C. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0161-0 · Cited by 31
Yang, J., Shen, N., Shen, J., Yang, Y., & Li, H.-L. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03867-x · Cited by 32
Akbari, V., Ghobadi, S., Mohammadi, S., & Khodarahmi, R. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108218 · Cited by 33
Zhao, A., Li, Y., & Deng, Y. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135392 · Cited by 31
Pushkarsky, T., Ward, A. R., Ivanov, A. I., Lin, X., Sviridov, D., Nekhai, S. A., & Bukrinsky, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02608-2 · Cited by 32
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Meyer, S. D., Vanbrabant, J., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Dupont, P. J., Laere, K. V., Stoops, E., Vanmechelen, E., Poesen, K., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51553 · Cited by 32
Lantero‐Rodriguez, J., Tissot, C., Snellman, A., Servaes, S., Benedet, A. L., Rahmouni, N., Montoliu‐Gaya, L., Therriault, J., Brum, W. S., Stevenson, J., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13119 · Cited by 30
Traumatic brain injury and the pathways to cerebral tau accumulation
Flavin, W. P., Hosseini, H. C., Ruberti, J. W., Kavehpour, H. P., Giza, C. C., & Prins, M. L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1239653 · Cited by 33
Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases
Trudler, D., Ghatak, S., & Lipton, S. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158196 · Cited by 30
Hubbard, E. E., Heil, L. R., Merrihew, G. E., Chhatwal, J. P., Farlow, M. R., McLean, C., Ghetti, B. F., Newell, K. L., Frosch, M. P., Bateman, R. J., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00558 · Cited by 33
Self-citationA Prospective Viewpoint on Neurological Diseases and Their Biomarkers
Zehravi, M., Kabir, J., Akter, R., Malik, S., Ashraf, G. M., Tagde, P., Ramproshad, S., Mondal, B., Rahman, M. H., Mohan, A. G., et al. (2022) · Molecules · doi:10.3390/molecules27113516 · Cited by 31
Brown, J., Camporesi, E., Lantero‐Rodriguez, J., Olsson, M., Wang, A., Medem, B., Zetterberg, H., Blennow, K., Karikari, T. K., Wall, M. J., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01562-5 · Cited by 32
In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
Toombs, J., & Zetterberg, H. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa054 · Cited by 30
Wojdała, A. L., Bellomo, G., Gaetani, L., Teunissen, C. E., Parnetti, L., & Chiasserini, D. (2025) · Nature Communications · doi:10.1038/s41467-024-54878-8 · Cited by 30
Lan, G., Wang, M., González‐Ortiz, F., Zhang, L., Li, A., Li, B., Jiang, M., Yang, J., Chen, X., Shi, D., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00904-3 · Cited by 31
Cai, N., Chen, J., Bi, D., Gu, L., Yao, L., Li, X., Li, H., Xu, H. Y., Hu, Z., Liu, Q., et al. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b07022 · Cited by 29
Acetylation of Aβ42 at Lysine 16 Disrupts Amyloid Formation
Adhikari, R., Yang, M., Saikia, N., Dutta, C., Alharbi, W. F. A., Shan, Z. J., Pandey, R., & Tiwari, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00069 · Cited by 29
The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 30
Blood based biomarkers for movement disorders
Morris, H. R. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13700 · Cited by 29
Wang, Y., Zhang, Z., Li, B., He, B., Li, L., Nice, E. C., Zhang, W., & Xu, J. F. (2022) · Antioxidants · doi:10.3390/antiox11112287 · Cited by 30
Kurihara, M., Matsubara, T., Morimoto, S., Arakawa, A., Ohse, K., Kanemaru, K., Iwata, A., Murayama, S., & Saito, Y. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01758-3 · Cited by 29
Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
Merluzzi, A. P., Vogt, N. M., Norton, D., Jonaitis, E. M., Clark, L. R., Carlsson, C. M., Johnson, S. C., Asthana, S., Blennow, K., Zetterberg, H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.004 · Cited by 28
The Mechanistic Role of Bridging Integrator 1 (BIN1) in Alzheimer’s Disease
Gao, P.-R., Ye, L., Cheng, H.-R., & Li, H. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00926-y · Cited by 34
Salvadó, G., Milà‐Alomà, M., Shekari, M., Minguillón, C., Fauria, K., Niñerola‐Baizán, A., Perissinotti, A., Kollmorgen, G., Buckley, C. J., Farrar, G., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12245 · Cited by 30
Wang, Y., Sun, Y., Luo, Y., Peng, D., Li, X., Yang, B., Wang, Q., & Kuang, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700587 · Cited by 29
Delrieu, J., Bateman, R. J., Touchon, J., Sabbagh, M., & Cummings, J. L. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.48 · Cited by 28
Self-citationModelling frontotemporal dementia using patient-derived induced pluripotent stem cells
Lines, G., Casey, J. M., Preza, E., & Wray, S. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103553 · Cited by 30
Sigurdsson, E. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231238 · Cited by 28
Brain injury markers in new-onset seizures in adults: A pilot study
Eriksson, H., Banote, R. K., Larsson, D., Blennow, K., Zetterberg, H., & Zelano, J. (2021) · Seizure · doi:10.1016/j.seizure.2021.08.012 · Cited by 27
Easton, A. E., Jensen, M. L., Wang, C., Hagedorn, P., Li, Y.-W., Weed, M. R., Meredith, J. E., Guss, V. L., Jones, K. M., Gill, M. B., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.027 · Cited by 27
The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease
Bendtsen, K. M., & Hall, V. J. (2023) · Cells · doi:10.3390/cells12030420 · Cited by 30
Rahimi, B., Behroozi, Z., Motamednezhad, A., Jafarpour, M., Hamblin, M. R., Moshiri, A., Janzadeh, A., & Ramezani, F. (2023) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-023-06711-9 · Cited by 27
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01206-2 · Cited by 30
The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults
Ennis, G. E., Betthauser, T. J., Koscik, R. L., Chin, N. A., Christian, B. T., Asthana, S., Johnson, S. C., & Bendlin, B. B. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01180-2 · Cited by 26
Precision proteoform design for 4R tau isoform selective templated aggregation
Longhini, A. P., DuBose, A., Lobo, S., Vijayan, V., Bai, Y., Rivera, E. K., Sala‐Jarque, J., Nikitina, A. A., Carrettiero, D. C., Unger, M., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320456121 · Cited by 26
Ellis, M. J., Lekka, C., Holden, K. L., Tulmin, H., Seedat, F., O'Brien, D. P., Dhayal, S., Zeissler, M., Knudsen, J. G., Kessler, B. M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02729-7 · Cited by 26
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 28
Conserved gene signatures shared among MAPT mutations reveal defects in calcium signaling
Minaya, M., Mahali, S. K., Iyer, A. K., Eteleeb, A. M., Martinez, R. J., Huang, G., Budde, J., Temple, S., Nana, A. L., Seeley, W. W., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1051494 · Cited by 29
Self-citationRoque, C. G., Chung, K. M., McCurdy, E. P., Jagannathan, R., Randolph, L. K., Herline, K., Baleriola, J., & Hengst, U. (2023) · Science Advances · doi:10.1126/sciadv.add2671 · Cited by 27
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 27
Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions
Croft, C. L., Goodwin, M. S., Ryu, D. H., Lessard, C. B., Tejeda, G., Marrero, M., Vause, A. R., Paterno, G., Cruz, P. E., Lewis, J. M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02264-9 · Cited by 26
Tau in the brain interstitial fluid is fragmented and seeding–competent
Barini, E., Plotzky, G., Mordashova, Y., Hoppe, J., Rodriguez-Correa, E., Julier, S., Prieult, F. L., Mairhofer, I., Mezler, M., Biesinger, S., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.013 · Cited by 28
Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry
Minikel, E. V., Kuhn, E. W., Cocco, A. R., Vallabh, S. M., Hartigan, C. R., Reidenbach, A. G., Safar, J., Raymond, G. J., McCarthy, M. D., O’Keefe, R., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001702 · Cited by 25
Snowden, T. M., Reid, H. M. O., Kennedy, S., Kenny, R., McQuarrie, A. M., Stuart-Hill, L. A., García-Barrera, M. A., Gawryluk, J. R., & Christie, B. R. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2020.7130 · Cited by 25
Onset of Preclinical Alzheimer Disease in Monozygotic Twins
Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., Mulder, S. D., Nivard, M. G., Vanderstichele, H., Lammertsma, A. A., Teunissen, C. E., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26048 · Cited by 25
Influence of traumatic brain injury on extracellular tau elimination at the blood–brain barrier
Eisenbaum, M., Pearson, A., Gratkowski, A., Mouzon, B., MULLAN, M. J., Crawford, F., Ojo, J. O., & Bachmeier, C. J. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00283-y · Cited by 26
Traumatic Brain Injury Biomarkers, Simulations and Kinetics
Hicks, C., Dhiman, A., Barrymore, C., & Goswami, T. (2022) · Bioengineering · doi:10.3390/bioengineering9110612 · Cited by 27
Defective proteostasis in induced pluripotent stem cell models of frontotemporal lobar degeneration
Mahali, S., Martinez, R., King, M., Verbeck, A., Harari, O., Benitez, B. A., Horie, K., Sato, C., Temple, S., & Karch, C. M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02274-5 · Cited by 33
Self-citationMultifaceted Roles of Aquaporins in the Pathogenesis of Alzheimer’s Disease
Yamada, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076528 · Cited by 26
Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
Eide, P. K., Lashkarivand, A., Pripp, A. H., Valnes, L. M., Hovd, M. H., Ringstad, G. A., Blennow, K., & Zetterberg, H. (2023) · Brain Communications · doi:10.1093/braincomms/fcad343 · Cited by 27
Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers
McGuigan, S., Evered, L. A., Scott, D. A., SILBERT, B. S., Zetterberg, H., & Blennow, K. (2021) · Medical Gas Research · doi:10.4103/2045-9912.324591 · Cited by 24
Ricci, M., Cimini, A., Camedda, R., Chiaravalloti, A., & Schillaci, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313002 · Cited by 24
Kasuga, K., Kikuchi, M., Tsukie, T., Suzuki, K., Ihara, R., Iwata, A., Hara, N., Miyashita, A., Kuwano, R., Iwatsubo, T., et al. (2022) · BMJ Neurology Open · doi:10.1136/bmjno-2022-000321 · Cited by 24
Bloomingdale, P., Yadav, D. B., Sugam, J. A., Grauer, S. M., Smith, B. E., Antonenko, S. V., Judo, M., Azadi, G., & Yee, K. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.867457 · Cited by 25
Cerebrospinal Fluid and Brain Proteoforms of the Granin Neuropeptide Family in Alzheimer’s Disease
Quinn, J. P., Ethier, E. C., Novielli, A., Malone, A., Ramirez, C. E., Salloum, L., Trombetta, B. A., Kivisäkk, P., Bremang, M., Selzer, S., et al. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00341 · Cited by 24
Bijttebier, S., Theunis, C., Jahouh, F., Martins, D. R., Verhemeldonck, M., Grauwen, K., Dillen, L., & Mercken, M. H. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462299 · Cited by 25
Injection of Cerium Oxide Nanoparticles to Treat Spinal Cord Injury in Rats
Behroozi, Z., Rahimi, B., Hamblin, M. R., Nasirinezhad, F., Janzadeh, A., & Ramezani, F. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac026 · Cited by 24
Wen, Q., Verheijen, M. C. T., Wittens, M. M. J., Czuryło, J., Engelborghs, S., Hauser, D. A., van Herwijnen, M. H. M., Lundh, T., Bergdahl, I. A., Kyrtopoulos, S. Α., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20305-5 · Cited by 23
Kandiah, N., Choi, S. H., Hu, C., Ishii, K., Kasuga, K., & Mok, V. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220059 · Cited by 25
Capillary dysfunction correlates with cortical amyloid load in early Alzheimer's disease
Madsen, L. S., Parbo, P., Ismail, R., Gottrup, H., Østergaard, L., Brooks, D. J., & Eskildsen, S. F. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.12.006 · Cited by 26
Metadata
- Authors
- Sato, C., Barthélemy, N. R., Mawuenyega, K. G., Patterson, B. W., Gordon, B. A., Jockel-Balsarotti, J., Sullivan, M., Crisp, M. J., Kasten, T., Kirmess, K. M., Kanaan, N. M., Yarasheski, K. E., Baker-Nigh, A., Benzinger, T. L. S., Miller, T. M., Karch, C. M., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Michigan State University (US)
- Corresponding author
- Sato, Chihiro
- Karch, Celeste M.
- Bateman, Randall J.
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 97
- Issue
- 6
- Pages
- 1284-1298.e7
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC6137722
- OpenAlex
- W2794390181
- Cited by
- 586
- References
- 82
- Citations by year
- 2026: 44 · 2025: 64 · 2024: 60 · 2023: 68 · 2022: 84 · 2021: 90 · 2020: 81 · 2019: 70 · 2018: 24
- FWCI
- 45.72
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-05-16)
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 385 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- BrightFocus Foundation (A2014384S)
- Tau SILK Consortium
- NIH (R01NS095773, R01NS078398, K01 AG046374, P30DK056341, P01AG003991, UL1TR000448, P30NS098577, P01AG026276, K01 AG053474, P50AG005681, P41GM103422, P30DK020579)
- MetLife Foundation
- Knight ADRC (P50AG05681)
- Coins for Alzheimer’s Research Trust
- Barnes-Jewish Hospital Foundation (UL1TR002345)
- 41st Kanae Foundation for the Promotion of Science Fellowship
- McDonnell Science Grant for Neuroscience
- ALS Association (2427)
- DIAN-TU Pharma Consortium
- Tau Consortium
- Alzheimer’s Association Research Fellowship (AARF-16-443265)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- tau protein, tau isoforms, tau phosphorylation, 4R tau, iPSC-derived neurons, human central nervous system, amyloid plaques, Alzheimer's disease, stable isotope labeling
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Brain, Cell Line, Cells, Cultured, Central Nervous System, Female, Humans, Kinetics, Male, Middle Aged, Biomarkers, tau Proteins, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
